SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zeev Hed who wrote (19)8/21/1996 11:43:00 PM
From: Josh C. Pleasure, M.D.   of 371
 
I wouldn't base potential for CEA-Scan on OncoScint. OncoScint stinks. You can't even find liver mets - the most common location for colorectal mets. Not to mention the 30% antibody formation rate.

By the way, Breast cancer CEA phase III trial starting within a matter of days to weeks. The first doses expected to arrive shortly. IMMU still trying to figure out what application to go for.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News